FDA new OTC drug products division acting director will be Debra Bowen.
This article was originally published in The Tan Sheet
Executive Summary
NEW OTC DRUG PRODUCTS DIVISION ACTING DIRECTOR WILL BE DEBRA BOWEN, MD, the current director of the Medical Review Staff. Under the upcoming reorganization of the Center for Drug Evaluation and Research (CDER), FDA is folding the current Office of OTC Drug Evaluation into one of five new offices of drug evaluation, ODE 5, to be headed by Michael Weintraub, MD, currently Office of OTC Drug Evaluation director.